1. Pfizer has acquired Metsera in a bidding war against Novo Nordisk for up to $10 billion, positioning itself in the obesity treatment market with promising drug candidates for metabolic diseases offering monthly dosing. This move allows Pfizer to enter the weight loss game after previous struggles in this space.
2. Peloton, once a pandemic favorite, is making a potential comeback as it shifts towards profitability by increasing operating leverage and focusing on new product launches like Peloton IQ. Despite subscriber losses, revenue is stabilizing and profitability is on the rise, making it a stock to watch for investors.
3. Circle’s phenomenal results show a 66% revenue increase to $740 million with USDC circulation up by 108% to $73.7 billion. Net income tripled to $214 million. Circle’s ARC Public Testnet aims to disrupt traditional payments by providing a blockchain built on the US dollar, potentially revolutionizing the financial industry.

Read more at Nasdaq: Can AI Drive Peloton’s Comeback?